mARC1 in MASLD: Modulation of lipid accumulation in human hepatocytes and adipocytes.
Amanda K JonesBesnik BajramiMorgan K CampbellAbdullah Mesut ErzurumluogluQiusha GuoHongxing ChenXiaomei ZhangSvetlana ZevelevaDavid KvaskoffAndreas-David BrunnerStefanie MullerVasudha GatheyRajvee M DaveJames W TannerSophia RixenMichel A StruweKathryn PhoenixKaitlyn J KlumphHeather RobinsonDaniel VeyelAnnkatrin MullerBoris NoyvertBoris Alexander BartholdyAgnes A Steixner-KumarJan StutzkiDmitriy DrichelSteffen OmlandRyan SheehanJon HillTom BretschneiderDirk GottschlingAxel J ScheidigBernd ClementMartin GieraZhihao DingJohn BroadwaterCurtis R WarrenPublished in: Hepatology communications (2024)
Depleting hepatocyte mARC1 improved metabolic dysfunction-associated steatotic liver disease-related outcomes. Given the functional role of mARC1 in human adipocyte lipid accumulation, systemic targeting of mARC1 should be considered when designing mARC1 therapies. Our data point to plasma lipid biomarkers predictive of mARC1 abundance, such as Ceramide 22:1. We propose future areas of study to describe the precise molecular function of mARC1, including lipid trafficking and subcellular location within or around the mitochondria and endoplasmic reticulum.